Sudan is a highly endemic area for hepatitis B virus (HBV), and >5% of blood donors are chronically infected. To examine potential strategies to improve HBV blood safety, 404 replacement donor samples previously screened for HBV surface antigen (HBsAg) were tested for antibody to HBV core (anti-HBc), anti-surface antigen (anti-HBs), and HBV DNA. Of 145 anti-HBc-containing samples (36%) identifi...

 ABSTRACT One of the best reliable markers of hepatitis B virus infection is antibodies to the core antigen (Anti-HBc). A first-time blood donor with HBsAg positivity was identified as an HBV carrier that was anti-HBc negative. The patient was followed for 24 months in order to investigate the evolution of his HBV serological profiles and HBVDNA (PCR). In the follow-up for 24 months, HBsAg, HBe...

UNLABELLED Phosphorylation of serines 157, 164, and 172 within the carboxyl-terminal SPRRR motif of the hepatitis B virus (HBV) core (C) protein modulates HBV replication at multiple stages. Threonine 162 and serines 170 and 178, located within the carboxyl-terminal conserved RRRS/T motif of HBV C protein, have been proposed to be protein kinase A phosphorylation sites. However, in vivo phospho...

BACKGROUND Patients with liver cirrhosis have usually poor antibody response to hepatitis B virus (HBV) vaccination. OBJECTIVES This study aimed to investigate the effect of granulocyte colony stimulating factor (G-CSF) on increasing antibody titers, after HBV vaccination, in patients with liver cirrhosis waiting for transplantation. PATIENTS AND METHODS From 56 patients with cirrhosis, 28 ...

BACKGROUND Little is known about the risk of hepatitis B virus (HBV) reactivation in patients receiving interferon (IFN)-free direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV). METHODS Patients who were seropositive for HBV core antibody and who received IFN-free DAAs for HCV were enrolled. Hepatitis B virus reactivation was defined as reappearance of serum HBV deoxyribonuclei...

BACKGROUND About ninety percent of immunocompetent adults recover from hepatitis B virus (HBV) infection within 6 months after transmission. The infection is considered to be terminated if the antibodies (HBsAb) to the hepatitis B surface antigen (HBsAg) become detectable and the HBsAg and Hepatitis B virus DNA (HBV DNA,) are no longer perceptible. After recovery from an acute infection, the de...

BACKGROUND A few cases of hepatitis B virus (HBV) reactivation during anti-viral therapy against hepatitis C (HCV) have been reported. However, the information regarding the real impact of this phenomenon is scarce. AIM To evaluate the risk of HBV reactivation during anti-viral therapy against HCV with an interferon-free regimen with direct-acting anti-virals (DAAs). METHODS Observational a...

6673 Background: Hepatitis B (HBV) re-activation and susequent liver damage during anti-cancer chemotherapy has been reported in a number of studies. As co-infection with HBV and the immunodeficiency virus-1 (HIV-1) is common, we examined the incidence and degree of HBV re-activation in a cohort of individuals with AIDS-related lymphoma (ARL). METHODS HBV viral load and surface antigen testin...

BACKGROUND Hepatitis B virus (HBV) and HIV are endemic in Uganda. Co-infection is common and leads to rapid progression of liver disease. Burden of co-infection is unknown yet most patients are on lamivudine-only ART where resistance is frequent. Most patients are initiated on antiretroviral therapy (ART) without knowing their HBV status. OBJECTIVES To determine burden of co-infection and HBV...